These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 33062062)

  • 1. FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules.
    Foschini F; Napolitano F; Servetto A; Marciano R; Mozzillo E; Carratù AC; Santaniello A; De Placido P; Cascetta P; Butturini G; Frigerio I; Regi P; Silvestris N; Delcuratolo S; Vasile E; Vivaldi C; Bianco C; De Placido S; Formisano L; Bianco R
    Ther Adv Med Oncol; 2020; 12():1758835920947970. PubMed ID: 33062062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOLFIRI-bevacizumab as a second-line treatment for advanced biliary tract cancer after gemcitabine-based chemotherapy.
    Roussot N; Vincent J; Palmier R; Constantin G; Bengrine L; Fumet JD; Ghiringhelli F
    Front Oncol; 2023; 13():1293670. PubMed ID: 38098503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative Dose Intensity of Chemotherapy and Survival in Patients with Advanced Stage Solid Tumor Cancer: A Systematic Review and Meta-Analysis.
    Nielson CM; Bylsma LC; Fryzek JP; Saad HA; Crawford J
    Oncologist; 2021 Sep; 26(9):e1609-e1618. PubMed ID: 33973301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of gemcitabine as second-line therapy after progression on FOLFIRINOX in advanced pancreatic cancer: a retrospective analysis.
    da Rocha Lino A; Abrahão CM; Brandão RM; Gomes JR; Ferrian AM; Machado MC; Buzaid AC; Maluf FC; Peixoto RD
    J Gastrointest Oncol; 2015 Oct; 6(5):511-5. PubMed ID: 26487945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer: A Real-life Experience and Outcome from a Tertiary Care Centre.
    Yasmeen S; Arshad F; Shaukat S; Badar F; Kazmi SAS; Ahmad U
    J Cancer Allied Spec; 2021; 7(2):e409. PubMed ID: 37197218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOLFIRI as second-line treatment of metastatic biliary tract cancer patients.
    Caparica R; Lengelé A; Bekolo W; Hendlisz A
    Autops Case Rep; 2019; 9(2):e2019087. PubMed ID: 31528622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of second-line chemotherapy in patients with advanced pancreatic adenocarcinoma: a real-world study.
    Liu Y; Guo X; Xu P; Song Y; Huang J; Chen X; Zhu W; Hao J; Gao S
    Cancer Biol Med; 2024 Jul; 21(9):799-812. PubMed ID: 39066473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of folfirinox for first-line treatment of metastatic pancreatic cancer.
    Attard CL; Brown S; Alloul K; Moore MJ
    Curr Oncol; 2014 Feb; 21(1):e41-51. PubMed ID: 24523620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Head-to-head comparison of treatment sequences in advanced pancreatic cancer-Real-world data from the prospective German TPK clinical cohort study.
    Marschner N; Haug N; Hegewisch-Becker S; Reiser M; Dörfel S; Lerchenmüller C; Linde H; Wolf T; Hof A; Kaiser-Osterhues A; Potthoff K; Jänicke M;
    Int J Cancer; 2024 Jul; ():. PubMed ID: 38956837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective comparison of the efficacy and the toxicity of standard and modified FOLFIRINOX regimens in patients with metastatic pancreatic adenocarcinoma.
    de Jesus VHF; Camandaroba MPG; Donadio MDS; Cabral A; Muniz TP; de Moura Leite L; Sant'Ana LF
    J Gastrointest Oncol; 2018 Aug; 9(4):694-707. PubMed ID: 30151266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes.
    Sridharan V; Mino-Kenudson M; Cleary JM; Rahma OE; Perez K; Clark JW; Clancy TE; Rubinson DA; Goyal L; Bazerbachi F; Visrodia KH; Qadan M; Parikh A; Ferrone CR; Casey BW; Fernandez-Del Castillo C; Ryan DP; Lillemoe KD; Warshaw AL; Krishnan K; Hernandez-Barco YG
    Pancreatology; 2021 May; ():. PubMed ID: 34023183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients.
    Schlick K; Hohla F; Hamacher F; Hackl H; Hufnagl C; Markus S; Magnes T; Gampenrieder SP; Melchardt T; Stättner S; Hauser-Kronberger C; Greil R; Rinnerthaler G
    Future Sci OA; 2020 Nov; 7(2):FSO644. PubMed ID: 33437513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exceptional response to FOLFIRINOX in a patient with pancreatic cancer and a germline
    Palacio S; Pollack T; Silva-Smith R; Sussman DA; Hosein PJ
    J Gastrointest Oncol; 2018 Aug; 9(4):E19-E22. PubMed ID: 30151275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel.
    Saito K; Nakai Y; Takahara N; Ishigaki K; Suzuki Y; Inokuma A; Noguchi K; Kanai S; Sato T; Hakuta R; Saito T; Hamada T; Mizuno S; Kogure H; Ijichi H; Tateishi K; Koike K
    Invest New Drugs; 2021 Apr; 39(2):605-613. PubMed ID: 33094362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared with Standard Concurrent Treatment in Preclinical Models of Pancreatic Cancer.
    Wolfe AR; Robb R; Hegazi A; Abushahin L; Yang L; Shyu DL; Trevino JG; Cruz-Monserrate Z; Jacob JR; Palanichamy K; Chakravarti A; Williams TM
    Clin Cancer Res; 2021 Jan; 27(2):554-565. PubMed ID: 33087331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer.
    Catalano M; Conca R; Petrioli R; Ramello M; Roviello G
    Cancer Manag Res; 2020; 12():10271-10278. PubMed ID: 33116881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combinatorial Approaches to Enhance DNA Damage following Enzyme-Mediated Depletion of L-Cys for Treatment of Pancreatic Cancer.
    Saha A; Zhao S; Chen Z; Georgiou G; Stone E; Kidane D; DiGiovanni J
    Mol Ther; 2021 Feb; 29(2):775-787. PubMed ID: 33091613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world outcomes associated with liposomal irinotecan dose reductions in metastatic pancreatic ductal adenocarcinoma.
    Kim GP; Surinach A; Corvino FA; Cockrum P; Belanger B; Abushahin L
    Future Oncol; 2021 Feb; 17(6):675-688. PubMed ID: 33070660
    [No Abstract]   [Full Text] [Related]  

  • 19. Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients.
    Volz NB; Hanna DL; Stintzing S; Zhang W; Yang D; Cao S; Ning Y; Matsusaka S; Sunakawa Y; Berger MD; Cremolini C; Loupakis F; Falcone A; Lenz HJ
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33065994
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.